The oral LD50 in rats and mice is >8000 mg/kg and 1540 mg/kg, respectively.L13904
Symptoms of oxazepam overdose are likely to be consistent with its adverse effect profile and range from mild to severe, sometimes fatal, CNS depression.L13895 Treatment should include gastric decontamination, via lavage or induced vomiting, followed by symptomatic and supportive measures. The benzodiazepine antagonist flumazenil may be used in hospitalized patients as an adjunct to non-pharmacological management, but may increase the risk of seizure in long-term benzodiazepine users and in cyclic antidepressant overdose.L13895
Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine lorazepam, is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.A203516 It is an active metabolite of both diazepam and temazepamA39486 and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.L13895
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Hydrocodone | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Magnesium sulfate | The therapeutic efficacy of Oxazepam can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Oxazepam may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Mirtazapine | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Orphenadrine | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Pramipexole | Oxazepam may increase the sedative activities of Pramipexole. |
| Ropinirole | Oxazepam may increase the sedative activities of Ropinirole. |
| Rotigotine | Oxazepam may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxazepam. |
| Suvorexant | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Thalidomide | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Clozapine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Clozapine. |
| Methadone | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. |
| Sodium oxybate | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Teduglutide | The serum concentration of Oxazepam can be increased when it is combined with Teduglutide. |
| Yohimbine | The therapeutic efficacy of Oxazepam can be increased when used in combination with Yohimbine. |
| Flumazenil | Flumazenil may decrease the sedative activities of Oxazepam. |
| Ethanol | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam. |
| Zimelidine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Oxazepam is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram. |
| Milnacipran | The risk or severity of adverse effects can be increased when Oxazepam is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Oxazepam is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Oxazepam is combined with Alaproclate. |
| Benzatropine | Benzatropine may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Disopyramide | Disopyramide may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Oxazepam. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Oxazepam. |
| Propantheline | Propantheline may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Dicyclomine | Dicyclomine may decrease the excretion rate of Oxazepam which could result in a higher serum level. |
| Tolterodine | Oxazepam may decrease the excretion rate of Tolterodine which could result in a higher serum level. |
| Flavoxate | Oxazepam may decrease the excretion rate of Flavoxate which could result in a higher serum level. |
| Tiotropium | Oxazepam may decrease the excretion rate of Tiotropium which could result in a higher serum level. |
| Fesoterodine | Oxazepam may decrease the excretion rate of Fesoterodine which could result in a higher serum level. |
| Aclidinium | Oxazepam may decrease the excretion rate of Aclidinium which could result in a higher serum level. |
| Trimebutine | Oxazepam may decrease the excretion rate of Trimebutine which could result in a higher serum level. |
| Imidafenacin | Oxazepam may decrease the excretion rate of Imidafenacin which could result in a higher serum level. |
| Propiverine | Oxazepam may decrease the excretion rate of Propiverine which could result in a higher serum level. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Oxazepam. |
| Imipramine | The risk or severity of CNS depression can be increased when Imipramine is combined with Oxazepam. |
| Doxepin | The risk or severity of CNS depression can be increased when Oxazepam is combined with Doxepin. |
| Desipramine | The risk or severity of CNS depression can be increased when Oxazepam is combined with Desipramine. |
| Zopiclone | The risk or severity of adverse effects can be increased when Oxazepam is combined with Zopiclone. |
| Caffeine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Caffeine. |
| Dyphylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Dyphylline. |
| Pentoxifylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Pentoxifylline. |
| Mercaptopurine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Mercaptopurine. |
| Oxtriphylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Oxtriphylline. |
| Theobromine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Theobromine. |
| Fenethylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Fenethylline. |
| 8-azaguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 8-azaguanine. |
| 7,9-Dimethylguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 7,9-Dimethylguanine. |
| Xanthine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Xanthine. |
| 7-Deazaguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 7-Deazaguanine. |
| Guanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Guanine. |
| 9-Methylguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 9-Methylguanine. |
| Peldesine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Peldesine. |
| Hypoxanthine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Hypoxanthine. |
| 9-Deazaguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 9-Deazaguanine. |
| Propentofylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Propentofylline. |
| Valomaciclovir | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Valomaciclovir. |
| 3-isobutyl-1-methyl-7H-xanthine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine. |
| Uric acid | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Uric acid. |
| Doxofylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Doxofylline. |
| 6-O-benzylguanine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with 6-O-benzylguanine. |
| Lisofylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Lisofylline. |
| Lobucavir | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Lobucavir. |
| Cafedrine | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Cafedrine. |
| Theodrenaline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Theodrenaline. |
| Bamifylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Bamifylline. |
| Proxyphylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Proxyphylline. |
| Acefylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Acefylline. |
| Etamiphylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Etamiphylline. |
| Pentifylline | The therapeutic efficacy of Oxazepam can be decreased when used in combination with Pentifylline. |